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The prevalence of dementia and cognitive impairment is rising worldwide as the number 
of elderly people increases in most countries.  Vascular risk factors and carotid artery 
atherosclerosis have in some epidemiological studies been associated with increased 
risk of cognitive decline.  The carotid artery is essential for blood supply to the brain, but 
is also vulnerable to atherosclerosis.   The degree of atherosclerosis in the carotid artery 
can easily be measured by ultrasonography.  
 
The population-based Tromsø study, with repeated screening surveys of the Tromsø 
population, has made it possible to follow participants prospectively.  Repeated carotid 
ultrasound scanning and cognitive test assessments have provided a unique opportunity 
for assessing change in atherosclerosis and change in cognitive test scores.  In this study 
we assessed the impact of different vascular risk factors on scores in three cognitive 
tests after 7 years of follow-up, and studied if carotid atherosclerosis and progression of 
atherosclerosis were independent risk factors for lower cognitive test scores and 
cognitive decline in a middle–aged stroke-free population.  
 
We found that diabetes, smoking and systolic blood pressure were consistent and 
independent risk factors for lower cognitive test results after 7 years follow-up in both 
genders. Physical inactivity was associated with lower scores in women.  Carotid 
atherosclerosis measured as total plaque area and number of plaques predicted lower 
scores on the verbal memory test 7 years later, whereas the average of plaque scores, 
measured at baseline and at follow-up, was associated with lower scores on all the 
cognitive tests in this study.  Progression of carotid plaques over 7 years was associated 
with lower scores on the digit symbol coding test and the tapping test.  We found no 







Forekomsten av kognitiv svekkelse og demens øker i takt med at det blir stadig flere 
eldre i samfunnet.  Vaskulære risikofaktorer og aterosklerose i carotisarteriene 
(halspulsårene) har i noen befolkningsstudier vært assosiert med økt risiko for kognitiv 
svekkelse.  Carotisarteriene forsyner store deler av hjernen med blod, men er samtidig 
utsatt for aterosklerose.  Graden av ateroslerose i carotisarteriene kan måles med 
ultralyd.   
 
Tromsøundersøkelsen er en befolkningsundersøkelse med gjentatte 
screeningundersøkelser som har gjort det mulig å følge deltakerne over mange år.   
Repeterte ultralydundersøkelser og testing av kognitiv funksjon har gitt oss en unik 
mulighet til å måle endring i aterosklerose og kognitive testskår over tid i de samme 
deltakerne.  Målet med denne studien var å se på ulike vaskulære risikofaktorers 
betydning for hvordan deltakerne skåret på tre kognitive tester 7 år senere, og å avgjøre 
om aterosklerose og progresjon av aterosklerose i carotisarteriene var uavhengige 
risikofaktorer for lavere skår på de kognitive testene og for fall i testskår fra 7-13 års 
oppfølging hos personer som ikke har hatt hjerneslag.   
 
Vi fant at diabetes, røyking og høyt blodtrykk var assosiert med dårligere kognitive 
testskår etter 7 års oppfølging. Fysisk inaktivitet var assosiert med lavere skår hos 
kvinner.  Aterosklerose i carotisarteriene, målt som totalt plakkareal eller antall plakk 
predikerte lavere skår på den verbale hukommelsestesten etter 7 år, mens 
gjennomsnittlig plakkskår mellom start og 7 års oppfølging var assosiert med lavere skår 
på alle de kognitive testene.  Progresjon av aterosklerose over 7 år var assosiert med 
lavere skår på tall-symbol koding test og på tappetesten.  Vi fant ingen assosiasjon 
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1.1 Epidemiology of dementia and cognitive impairment  
Cognitive impairment and dementia are major health problems worldwide.  By linear 
extrapolation of estimates from 2005, about 35 million people suffer from dementia 
worldwide, and the prevalence is expected to double every 20 years provided that no 
effective preventive strategy becomes available and no change in mortality (1). Forty-
three percent of dementia cases will be in need of a high level of health care equivalent 
to that of a nursing home (2).  The prevalence of dementia and cognitive impairment 
increases by age, and in a study based on 11 European cohorts on persons above 65 
years of age, the age-standardized prevalence of dementia (all causes) was found to be 
6.4 %, increasing from 0.8% in the group 65-69 years to 28.5% at age  90 years and 
older. The frequency nearly doubles every 5 years of age over 65 years (3). Some studies 
on American populations found even higher prevalence estimates (4, 5), but the 
prevalence seems to be similar in most Western societies (Figure 1).   
 
 
Figure 1. Global prevalence of dementia by age-groups.  Based on data from Ferri et. Al. Global       
                 prevalence of dementia: a Delphi consensus study. Lancet 2005; 366:211-17 (1) 
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If cases of mild cognitive impairment (MCI) are taken into account, the total prevalence 
of cognitive impairment will probably be the double of what is estimated of dementia 
alone, depending on how MCI is defined (6-8).  Because of increased life expectancy due 
to better health care and living conditions, and large birth rates in the years after World 
War II, a demographic shift towards a higher proportion of elderly is expected in the 
next decades in most Western countries.  In Norway the proportion of elderly over 67 
years of age is expected to double in the next 30-40 years (Figure 2). Unless better 
prevention strategies or treatment options become available, this will lead to a 




Figure 2. Population projection of the number of people 67 years or older in Norway from 2012  
                 to 2050.  Based on estimates from Statistics Norway (Statistisk sentralbyrå). 
 
 
Alzheimer’s disease (AD) is the major subtype of dementia, accounting for 65-70% of all 
cases, followed by vascular dementia (VaD) with 15-25% (3, 5).  Alzheimer’s disease 
progresses slowly over several years from normal cognitive function through MCI to 
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dementia, which gives a window for possible preventive efforts (6). Vascular dementia is 
caused by cerebral vascular lesions, and may occur acutely as a result of a strategic 
stroke or progressively due to several consecutive minor strokes or hypoperfusion to 
the brain. Identification and modification of risk factors in order to avoid or to delay the 
development of the two major types of dementia, may have great impact on public 
health.  For example a 5 year delay in the onset of AD could reduce the prevalence of AD 
by 50%. The estimated worldwide prevalence of AD alone is predicted to reach more 
than 100 million people in 2050, which means that 1 in 85 persons worldwide will have 
AD. If interventions could delay both disease onset and progression by only 1 year, there 
would be nearly 9.2 million fewer cases of AD worldwide in 2050, with nearly the entire 
decline attributable to decrease in persons needing a high level of health care (2).   
 
No current treatment can restore already non-functioning and lost neurons in 
demented patients, and treatment aimed at reversion of an existing brain damage is not 
likely to appear in the nearly coming years. To decrease the burden of dementia, the 
focus should therefore be on either primary prevention or secondary prevention to stop 
the progression of dementia in early stages. Primary and secondary prevention of VaD is 
in some degree possible by reduction of vascular risk factor levels and prevention of 
vascular disease.  Currently, only symptomatic treatment is available for AD 
(cholinesterase inhibitors and the NMDA-receptor antagonist memantine). Disease- 
modifying drug have been tested, but results have so far been disappointing (9, 10).  An 
effective primary prevention strategy would be the most preferable both to patient and 
society, but has so far not been established. Revealing possible treatable risk factors for 
cognitive impairment and dementia would be the first step toward a preventive strategy 
to lower the burden of cognitive impairment and dementia in society. Risk factors for 
prevalent diseases and symptoms can be assessed in cohort studies.  Exploring risk 
factors for cognitive impairment in general populations could give valuable information 





1.2 Vascular risk factors and relation to cognitive impairment and dementia 
Dementia caused by vascular changes was in the early days of modern medicine 
referred to as senile dementia due to hardening of arteries, but was replaced by the 
term multi-infarct dementia that was introduced in the late 1960s (11).  The concept of 
vascular dementia gained ground in the early 1990s in order to refine the description of 
dementias caused by cerebral vascular changes. Vascular dementia was defined as 
dementias caused by multi-infarcts, strategic single infarcts, hemorrhages, cerebral 
small vessel disease, or hypoperfusion of the brain, with several subgroups (12, 13).  
However, the magnitude of vascular changes needed to cause dementia has been 
difficult to define, and this together with different clinical and research criteria in use, 
have given rise to a debate about the concept of vascular dementia (14).  In recent 
years, the term vascular cognitive impairment is used to cover the whole scale from 
mild cognitive impairment to dementia caused by vascular changes, as well as cases of 
mixed dementias of vascular and degenerative causes (15).  Risk factors for vascular 
cognitive impairment are thought to be the same as for stroke and include the 
traditional vascular risk factors; hypertension, smoking, high total-cholesterol, diabetes, 
physical inactivity and heavy alcohol consumption in addition to atherosclerosis, atrial 
fibrillation, heart failure, high age and low socioeconomic status (11, 15, 16).   
 
In the first years after Alois Alzheimer described the disease of his famous patient 
Auguste D. in 1906, AD was thought to be a rare degenerative pre-senile dementia, 
while senile dementia caused by cerebral arteriosclerosis was perceived as the 
dominating cause of dementia. The pathological hallmarks of AD were amyloid plaques 
and intraneuronal tangles.  Although some early investigators believed that also AD 
could be caused by cerebral arteriosclerosis, pathological studies in the mid- 20th 
century found an inconsistent relationship between AD and cerebral atherosclerosis, 
and AD was classified as a pure degenerative disease (17).  In the beginning of the 
1990s, pathological studies found that apolipoprotein E (APO E), involved in cholesterol 
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transport, was a constituent of amyloid plaques in Alzheimer’s disease patients (18, 19).  
An association between the epsilon 4 (ε4) genotype of APO E and increased risk of AD 
was found in epidemiological studies, and led to a new interest in vascular changes in 
AD (20). During the last twenty years epidemiological studies have found associations 
between the vascular risk factors smoking, hypertension, high total-cholesterol, 
diabetes, physical inactivity, obesity and AD (21-24).   Also, pathological studies have 
found that cerebral vascular changes is not unusual in AD, leading to the concept of 
mixed dementia of VaD and AD (25).  Some authors have proposed that the 
neurodegenerative process of late-onset sporadic Alzheimer’s disease may be triggered 
by vascular changes (26).  If this is true, vascular risk factors and atherosclerosis could 
contribute to 80-90% of all cases of dementia.   
 
1.3 Carotid atherosclerosis and relation to cognitive impairment and dementia 
Atherosclerosis is a pathological process of the arterial wall, which in advanced stages 
cause vessel narrowing and occlusion. The traditional risk factors for cardiovascular 
disease and stroke, such as hypertension, smoking, total cholesterol and diabetes are 
also risk factors for progression of atherosclerosis (27, 28).  The carotid arteries are 
vulnerable to atherosclerosis, and because they supply blood to the brain, vessel 
narrowing and embolisms from carotid atherosclerosis could cause stroke and 
subsequent cognitive impairment (29, 30).  Some studies also found that carotid 
atherosclerosis was independently associated with poorer cognitive function in subjects 
without a clinical stroke (31, 32).  
 
Ultrasound is an easily assessable and non-invasive method to measure the different 
stages of the atherosclerotic process in the carotid artery. The arterial wall consists of 
three layers, the intima, the media and the adventitia.  Atherosclerosis is mainly an 
intimal process with deposition of cholesterol, inflammation and cell infiltration. 
Ultrasound cannot distinguish between the intima- and media-layer, but the intima-
media thickness (IMT) of the arterial vessel wall can be assessed (29).  Atherosclerotic 
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plaques usually occur at sites of non-laminar turbulent flow such as the carotid 
bifurcation and the proximal internal carotid artery (ICA), and measurement of 
thickening in the arterial intima-media layer in these areas are likely to represent early 
stages in the atherosclerotic process. However, a diffuse thickening of the carotid artery 
intima-media layer can also represent a hypertensive hypertrofic response of the 
smooth muscle cells of the medial-layer related to changes in local shear stress and 
tensile stress to the vessel wall. In clinical and epidemiological studies IMT has usually 
been measured in the near and the far wall of the distal part of the common carotid 
artery (CCA-IMT), the carotid bifurcation (Bulb-IMT) and the proximal internal carotid 
artery (ICA-IMT).  
 
Atherosclerotic plaques are localized manifestations of atherosclerosis. Criteria for 
ultrasound definition of an atherosclerotic plaque have varied in different studies (33). A 
visually localized protrusion of the vessel wall of more than 50% of the adjacent 
(normal) IMT is a widely used definition of a plaque and is also used in the Tromsø study 
(34).  Plaque occurrences, number of plaques, plaque thickness, plaque area, plaque  
volume and plaque echogenicity are different measures that can be used to assess the 
amount and burden of carotid atherosclerosis. Small plaques do not significantly affect 
the blood flow or blood velocity, but increasing plaque size or number leads to 
narrowing of the vessel lumen, stenosis and increased risk of embolization and 
hypoperfusion. Compared to early intima-media thickening, formed plaques represent 
more advanced atherosclerosis. Studies have indicated that total plaque burden 
measured as total plaque area, the sum of all plaque areas in the distal CCA, bifurcation 
and proximal ICA, may be a sensitive tool for prediction of clinical cardiovascular disease 
(35). Previous studies have found that total plaque area predicts future stroke and 
myocardial infarction (36, 37).  In the Tromsø Study, total plaque area was a stronger 




Previous population-based studies on the relation of carotid atherosclerosis and 
cognitive function have assessed the impact of a one-time measure of atherosclerosis.  
Most of the studies have focused on the impact of carotid IMT and stenosis and not 
carotid plaques, and no population-based studies have assessed the progression of 
carotid plaques in relation to cognitive function (40).  In some studies, cognitive 
impairment and decline were independently predicted by both carotid IMT (32, 41, 42) 
and carotid stenosis (31, 32, 43), but results are conflicting as some studies in middle-
aged populations did not observe the same relationship (23, 44).  In two studies, carotid 
IMT, but not carotid stenosis or atherosclerotic plaques, was associated with increased 
risk of AD (45, 46). Little is known about how carotid atherosclerosis in middle age 
affects cognitive test scores, as most studies are done in the elderly (>65 years). 
Measurements of progression of carotid atherosclerosis over years could bring stronger 
















2. Aims of the thesis 
 
The general objective of this thesis was to study possible preventable risk factors for 
cognitive impairment in the general population.  
 
The specific aims were: 
 
- To assess and compare the impact of traditional cardiovascular risk factors on cognitive 
test scores after 7 years of follow-up in a stroke-free middle-aged general population. 
 
-To study if ultrasound-assessed carotid atherosclerosis measured as IMT, the number 
of plaques and total plaque area is associated with lower cognitive test results in a 
stroke-free middle-aged general population after 7 years of follow-up.  
 
-To explore if progression of carotid atherosclerosis from baseline to 7 years follow-up is 
associated with lower cognitive test scores at 7 years follow-up and with cognitive 












3. Subjects and methods 
3.1 Study population-The Tromsø study 
Subjects were participants in The Tromsø Study, a longitudinal population-based study 
in the municipality of Tromsø, Norway (47). A total of six cross-sectional screening 
surveys (Tromsø 1-6) with 6-7 years interval have so far been carried out from 1974 until 
2008. Cardiovascular disease was initially the main focus of the study, but other 
research areas have been added throughout the years. Ultrasound examination of the 
right carotid arteries was done the first time in Tromsø 4 in 1994/1995, and repeated in 
Tromsø 5 in 2001/2002 and in Tromsø 6 in 2007/2008. Cognitive testing was done in 
Tromsø 5 and 6. The Tromsø population is mainly Caucasian.  In 1994/1995, less than 
2% of the population was immigrants of non-Western origin. All subjects who 
participated in Tromsø 4-6 were asked to give written consent to medical research.  
They are free to withdraw their consent at any time, and also to give new consent later 
on, for example when participating in a new survey.  Thus, the number of participants 
with valid written medical consent may vary over time.   
 
Tromsø 4 comprised two screening visits 4-12 weeks apart. To the first visit, all citizens 
aged 25 and above were invited, and 27158 attended (77% attendance rate). All 
participants who were between 55-74 years old and 5-10% samples of the remaining 5-
year birth cohorts aged 25-85 years were invited to a more comprehensive second visit 
examination, and the 7965 subjects who attended (76% of the eligible) constituted the 
baseline for this study (Figure 3).  Vascular risk factors were assessed in in the 1st visit in 
Tromsø 4, and carotid ultrasound examination was performed in 6727 subjects who 
attended the 2nd visit (1238 subjects not scanned for logistic reasons). All subjects who 
attended both visits of Tromsø 4 and who were still registered as inhabitants of Tromsø 
(n=6969) were invited to the 2nd visit in Tromsø 5, and 5939 subjects attended (85%)1.  A 
total of 5493 subjects attended cognitive testing in Tromsø 5 (446 subjects not tested 
because of logistic reasons). Of those who underwent carotid ultrasound examination in 
                                                 
1 Not 6982 (invited) and 5898 (attended) as stated in Paper I and II.  
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Tromsø 4, 4858 subjects were rescanned in Tromsø 5. All individuals who had taken part 
in the 2nd visit of Tromsø 4 as well as individuals who were aged 50-62 or 75-84 and a 20 
% random sample of subjects aged 63-74 were invited to the 2nd visit of Tromsø 6, and 
7307 attended. Of those eligible who also attended Tromsø 4, the attendance rate was 
74 %.  A total of 2737 subjects attended cognitive testing in both Tromsø 5 and 6.   
 
In Paper I we investigated to role of cardiovascular risk factors assessed in Tromsø 4 in 
relation to cognitive test scores in stroke-free individuals after 7 years follow-up in 
Tromsø 5. Of the 5493 subjects who attended both visits of Tromsø 4 and cognitive 
testing in Tromsø 5, 512 did not have a valid written consent to medical research when 
the dataset was generated in 2007 and were excluded from analyses, leaving 5442 
subjects with valid data on cognitive testing.  We excluded 101 subjects with self-
reported stroke prior to participation in the cognitive testing in Tromsø 5, and 308 
subjects who did not have complete baseline data on the cardiovascular risk factors 
used in the analyses, leaving 5033 subjects who were included in Paper I.  
 
In Paper II we investigated the association between ultrasound-assessed carotid 
atherosclerosis in Tromsø 4 and cognitive testing in Tromsø 5. Of the 5493 who 
attended both visits in Tromsø 4 and attended cognitive testing in Tromsø 5, 31 was 
excluded for not having a valid written consent to medical research when the dataset 
was generated in 2011.  Participants of the Tromsø study are being followed-up with 
registration of incident stroke and other cardiovascular diseases. Strokes are identified 
through linkage to diagnosis registry at the University Hospital of North Norway (UNN) 
and the national Cause of Death Registry, and adjudication of hospitalized and out-of 
hospital first-ever strokes is performed by an independent endpoint committee based 
on data from hospital and out-of hospital journals (48). Based on these data, 192 
subjects were excluded due to previous validated stroke prior to cognitive testing, 635 
                                                 
2 Not 54, as stated in Paper I.  The number 54 referred to the 51 and additional 3 more subjects without 
consent who participated in the 2nd visit of Tromsø 5, but not in cognitive testing. 
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due to lack of carotid ultrasound data at baseline, and 264 due to incomplete data on 
cardiovascular risk factors, leaving 4371 in the cohort of Paper II.   
 
In Paper III we studied the association between the progression of carotid 
atherosclerosis from Tromsø 4 to 5 and cognitive test scores in Tromsø 5 and cognitive 
decline from Tromsø 5 to 6.  Of the 5493 who attended both visits of Tromsø 4 and 
cognitive testing in Tromsø 5, 31 was excluded for not having a valid written consent to 
medical research (in 2011), 195 were excluded due to validated stroke prior to cognitive 
testing in Tromsø 5. Three more strokes than in Paper II were identified in a new update 
of the stroke registry that took place in the period between Paper II and III. Baseline 
carotid ultrasound data were lacking in 609 subjects and 267 subjects had incomplete 
baseline data of cardiovascular risk factors and were excluded.  Follow-up carotid 
ultrasound data were lacking in 117 individuals, leaving 4274 subjects who were 
included in the study.  Of these subjects, 2100 were re-tested with at least one of the 
three cognitive tests in Tromsø 6.  Subjects with a validated diagnosis of stroke in the 
follow-up period from Tromsø 5 to 6 (n=58) were excluded from analyses, leaving a 
subgroup of 2042 subjects who were included in the second part of the study.  
 
Information about the study population and the number of subjects in each paper is 
summed up in a flow chart (Figure 3).  The studies were approved by the Regional 
Committee for Medical and Health Research Ethics, the Data Inspectorate and the 
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31 no valid consent 
195 strokes 
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267 incomplete baseline         
data on vascular risk factors 












Paper III  




3.2 Cardiovascular risk factors 
At baseline in Tromsø 4, two self-administrated questionnaires were filled in, non-
fasting blood samples were taken, and standardized measurement of weight, height, 
and blood pressure were performed. Blood pressure was recorded with an automatic 
device (Dinamap Vital Signs Monitor, Tampa, FL, USA) by specially trained personnel. 
Body mass index (BMI) was calculated as weight in kilograms divided by the square of 
the height in meters. Non-fasting serum cholesterol and triglycerides were analyzed by 
standard enzymatic methods.  Analyzes were performed at the Department of Clinical 
Chemistry, University Hospital of North-Norway. Information on education, smoking 
habits, physical activity, depression, diabetes, stroke and coronary heart disease were 
obtained from self-administered questionnaires (Appendix A). Education was assessed 
in four categories, primary/part secondary school (7-10 years), secondary/O-level (11-12 
years), high school/A-level and college/university less than 4 years (12-15 years) and 
college/university 4 years or more (>15 years). Smoking was defined as daily smoking of 
sigarettes, cigars or smoking a pipe. Physical activity was assessed by two questions on 
how many hours of light and hard physical activity the participants performed per week. 
Light activity was defined as not sweating or out of breath and hard physical activity was 
defined as sweating/out of breath. Answers were dichotomized to physically active and 
inactive groups, where physically active was defined as exercise with sweating/out of 
breath ≥ 1 hour per week, or ≥ 3 hours per week of light activity without sweating/out 
of breath. Diabetes was defined as self-reported diabetes and/or regular use of insulin 
or oral antidiabetics. Coronary heart disease was defined as previous myocardial 
infarction and/or prevalent angina. Depression was assessed by the question ‘Have you 
in the last two weeks felt down/depressed?’, where answers in the two upper of four 
categories (no, a little, a lot, or very much) were defined as depression. Use of 






3.3 Carotid ultrasound examination 
B-mode ultrasonography was performed with an Acuson Xp10 128, ART-upgraded 
duplex scanner equipped with a 7.5 MHz linear array transducer. Different sonographers 
did the baseline and follow-up scanning, and to ensure equal and standardized 
examination techniques and measurement procedures, all sonographers completed a 2-
month pre-study training protocol following the guidelines in Appendix E. Details about 
the ultrasound methods and reproducibility have been published previously (34, 49, 50). 
Due to logistic reasons, only the right carotid artery was scanned. The far- and near 
walls of the right CCA, bulb and ICA were scanned for plaque presence. A plaque was 
defined as a localized protrusion into the vessel lumen with thickening of the vessel wall 
of more than 50% compared to the adjacent IMT (Figure 4).  
Figure 4. The carotid bifurcation with an atherosclerotic plaque in a typical location in the far    
                  wall of the bulb. The adjacent IMT is visible on both sides of the plaque.  
 
Total plaque area was calculated as the sum of all plaque areas (34). Standardized 





the CCA far wall (CCA-FW-IMT) and near wall (CCA-NW-IMT)  and the far wall of the bulb 
(BULB-FW-IMT) (33), and mean IMT from 3 pre-selected images was calculated for each 
location and referred to as the mean total IMT. If present in the predefined location of 
interest, plaques were included in the IMT measurements. Final reading of both IMT and 
plaque data was done off line by the researchers. Measurements of IMT were analysed 
off line by a semi-automated computerized edge-detection program (51).  
 
3.4 Cognitive testing 
Three cognitive tests were chosen by a group of neuropsychologists and epidemiologists 
for use in Tromsø 5.  All tests were chosen because of their ability to detect early 
cognitive decline and their feasibility as screening tests in an epidemiological setting 
with a large number of participants.  The tests had previously been found to predict 
cognitive decline in other population-based studies (42, 52).  
 
The twelve word memory test is a test of short time verbal memory with immediate free 
recall of 12 nouns shown written on a board and also pronounced one at a time with a 
5-second interval (52). The participants then had 2 min to recall the words, and one 
point was given for each word correctly recalled.  
 
Digit-Symbol Coding test, a part of the Wechsler Adult Intelligence Scale (WAIS) is used 
to examine psychomotor speed, attention and mental flexibility (53). The digit-symbol 
substitution task consists of rows containing small blank squares, each paired with a 
randomly assigned number from one to nine and with a printed key above that pair 
each number with a different nonsense symbol (Appendix F).  Subjects were asked to 
consecutively fill in as many as possible of the blank spaces with the corresponding 
symbol as quickly and accurately as possibly over 90 seconds.  
 
Tapping test is a test mainly of psychomotor tempo. The subjects were instructed to tap 
as many times as possibly in 10 seconds with their index finger on a computer which 
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registered the number of taps. The task was repeated four times with both dominant 
hand and non-dominant hand (54). The mean of the average score of the three last trials 
on each hand was used in the analyses.  
 
3.5 Statistical methods 
The SAS statistical software package (SAS®, V9.2, SAS Institute Inc., Cary, NC, USA) was 
used for all statistical analyses. Baseline characteristics were presented as means 
(standard deviation) or numbers (percent) in the three papers.  In paper I, the 
association between vascular risk factors and cognitive test results were assessed in a 
multivariable linear regression model adjusted for age, education, systolic blood 
pressure, total-cholesterol, HDL-cholesterol, body mass index, current smoking, physical 
activity, diabetes, coronary heart disease and self-reported depression, and presented 
separately for men and women.  All continuous variables were dichotomized to fit a 
logistic regression model to measure the risk of scoring in the lowest quintile on each 
cognitive test. Descriptive statistics on scores and change in scores on cognitive tests 
and carotid atherosclerosis were presented in paper II and III.  The relation between 
different measures of carotid atherosclerosis scores and cognitive test results were 
assessed in univariable and multivariable regression models adjusted for sex, age, 
education, depression and vascular risk factors. Standardized regression coefficients 
were used as effect size to compare results between the independent variables (paper 
I), and also between each cognitive test (paper II and III).  The model assumptions were 
confirmed by graphical inspection of residuals. Possible two-way interactions were 
assessed by adding to the models cross product terms between each of the exposure 
variables and each of the adjustment variables. Multicollinearity between the 
independent variables was low, with a variance inflation factor < 1.6 for all variables in 






4.  Results 
Paper I - Impact of cardiovascular risk factors on cognitive function. The Tromsø Study. 
In this study we assessed the impact of different cardiovascular risk factors on cognitive 
test results in a stroke-free middle-aged general population (mean age 58.2 years in 
women and 58.8 years in men). Performance on the three cognitive tests is shown by 
sex, age and education level in table 1 (same as Webtable 1, Paper 1).  Increasing age 
and lower education level were consistently associated with lower cognitive 
performance on all three tests.  
 
In the multivariable linear regression analyses adjusted for age, education level, 
depression and vascular risk factors, smoking showed the most consistent inverse 
association with cognitive test results on all tests in both men and women. Physical 
activity was associated with better performance on the verbal memory test and the 
coding test in women, but no association was seen in men.  Systolic blood pressure was 
inversely associated with cognitive performance on the coding and the tapping test in 
women, and on the verbal memory test in men.  Diabetes was significantly associated 
with lower scores on the tapping test and the coding test in women, and on the verbal 
memory test and the coding test in men. We found no significant associations between 
total-cholesterol, HDL-cholesterol or coronary heart disease and any of the cognitive 
tests. BMI was negatively associated with performance on the coding test in men.  
 
In the logistic regression models, diabetes showed the strongest estimates for lower test 
scores.  The odds ratio (OR) of a score in the lowest quintile on the verbal memory test 
in men was 2.98 (95% CI 1.56-5.68), and 2.33 (95 % CI 1.25-4.35) on the coding test and 
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 Education Age years      
  25-49y (n) 50-54y (n) 55-59y (n) 60-64y (n) 65-69y (n) >70y (n) 
 
Verbal memory test     Scores are given as the number of right words recalled 
Men Primary school 6.93 (89) 5.98 (58) 5.86 (207) 5.27 (226) 5.05 (166) 4.64 (109) 
 Secondary school 7.25 (95) 6.71 (49) 6.37 (158) 5.82 (132) 5.45 (85) 5.17 (72) 
 High school/College<4y 7.85 (73) 6.93 (43) 6.59 (94) 6.58 (72) 6.30 (57) 5.41 (27) 
 College/university ≥4y  8.31 (36) 8.33 (18) 8.00 (62) 6.82 (22) 6.18 (22) 6.50 (12) 
Women Primary school 7.40 (60) 6.64 (235) 6.17 (341) 5.99 (291) 5.58 (307) 4.85 (217) 
 Secondary school 7.91 (99) 7.02 (118) 7.17 (141) 6.52 (92) 6.12 (102) 5.79 (34) 
 High school/College<4y 8.10 (89) 7.82 (72) 7.64 (59) 7.07 (45) 6.97 (34) 5.65 (17) 
 College/university ≥4y  9.12 (47) 8.31 (42) 7.36 (53) 6.93 (28) 7.00 (10) 6.71 (7) 
 
Coding test                Scores are given as the number of right symbols coded 
Men Primary school 34.83 (89) 31.05 (59) 27.42 (219) 21.94 (235) 19.48 (182) 16.53 (118) 
 Secondary school 42.48 (97) 36.54 (46) 31.95 (155) 27.27 (132) 25.34 (90) 20.88 (72) 
 High school/College<4y 49.85 (72) 39.84 (45) 38.02 (98) 33.34 (71) 28.30 (60) 26.68 (28) 
 College/university ≥4y  48.71 (38) 47.72 (18) 42.85 (65) 39.14 (22) 35.22 (22) 30.83 (12) 
Women Primary school 44.19 (63) 33.43 (237) 29.04 (349) 24.46 (300) 21.65 (310) 17.05 (232) 
 Secondary school 48.05 (95) 40.51 (122) 35.32 (151) 31.08 (93) 28.58 (106) 25.83 (36) 
 High school/College<4y 52.04 (93) 48.21 (72) 38.97 (62) 32.60 (48) 33.53 (34) 27.29 (17) 
 College/university ≥4y  55.36 (47) 47.05 (41) 40.75 (53) 37.14 (29) 38.11 (9) 33.14 (7) 
 
Tapping test dominant hand    Scores are given as the average number of taps in 10 seconds 
Men Primary school 61.56 (98) 57.45 (58) 56.29 (234) 53.13 (243) 51.22 (186) 47.99 (128) 
 Secondary school 62.57 (106) 59.20 (46) 58.27 (171) 56.29 (139) 52.87 (92) 51.78 (76) 
 High school/College<4y 62.40 (72) 62.20 (45) 61.26 (100) 57.58 (74) 55.40 (56) 51.54 (29) 
 College/university ≥4y  64.57 (36) 61.96 20) 62.66 (71) 58.75 (24) 56.61 (24) 51.78 (13) 
Women Primary school 54.52 (63) 51.80 (249) 51.06 (376) 48.63 (313) 46.31 (318) 41.01 (236) 
 Secondary school 58.75 (96) 54.80 (125) 54.74 (158) 52.47 (98) 49.78 (107) 44.51 (36) 
 High school/College<4y 60.78 (97) 58.25 (71) 56.85 (65) 53.28 (50) 52.58 (38) 47.66 (18) 
 College/university ≥4y  59.68 (49) 58.13 (42) 55.93 (53) 53.86 (29) 53.59 (14) 50.24 (7) 
 
Tapping test non-dominant hand    Scores are given as the average number of taps in 10 seconds 
Men Primary school 57.01 (98) 53.98 (56) 51.72 (234) 49.59 (243) 45.96 (186) 43.72 (128) 
 Secondary school 58.52 (106) 55.41 (49) 53.78 (171) 51.59 (139) 47.37 (92) 47.17 (76) 
 High school/College<4y 58.41 (76) 56.17 (45) 56.61 (100) 57.58 (71) 51.47 (56) 47.54 (29) 
 College/university ≥4y  61.84 (36) 55.59 (20) 57.40 (71) 58.75 (24) 51.09 (24) 45.79 (13) 
Women Primary school 50.47 (63) 48.26 (249) 46.94 (376) 44.45 (313) 42.57 (318) 38.06 (217) 
 Secondary school 53.87 (96) 49.75 (125) 49.78 (158) 48.09 (98) 44.46 (107) 40.81 (36) 
 High school/College<4y 56.30 (97) 53.56 (71) 56.85 (65) 48.62 (50) 47.49 (38) 46.16 (18) 
 College/university ≥4y  55.13 (49) 53.12 (42) 50.99 (53) 47.98 (29) 47.97 (14) 44.33 (7) 
29 
 
Paper II - Carotid atherosclerosis predicts lower cognitive test results: A 7 years follow-
up study in 4371 stroke-free subjects. The Tromsø Study.   
In this paper we studied the association between ultrasound-assessed carotid 
atherosclerosis and cognitive test scores after 7 years follow-up in stroke-free subjects.  
Atherosclerotic plaques were found in 40.7% of women and 49.6% of men. In the 
multivariable analyzes adjusted for sex, age, education, depression and vascular risk 
factors, plaque presence was significantly associated with lower test scores on the 
verbal memory test (p=0.01) and on the digit-symbol coding test (p=0.03). The number 
of plaques (p=0.01) and the total plaque area (p=0.02) were associated with lower 
scores on the verbal memory test. The mean total IMT was negatively associated with 
the digit-symbol coding test, but CCA-FW-IMT did not show any association with the 
cognitive tests. There were no independent associations between the carotid ultrasound 
variables and the tapping test.  
 
Paper III - Carotid artery plaque progression and cognitive decline. The Tromsø Study 
1994-2008. 
The aim of the study was to assess if progression of carotid atherosclerosis in stroke-
free subjects was associated with lower cognitive test scores and cognitive decline.  
From Tromsø 4 to 5, the prevalence of plaques increased from 44.5 % to 61.0 %, the 
average total plaque area increased from 8.7 mm² to 14.8 mm² and there was a shift 
toward a higher number of plaques.  In all cognitive tests we observed a small decline in 
test results over the 6 years from Tromsø 5 to 6. In multivariable regression models 
adjusted for sex, age, education, depression and vascular risk factors, the average of 
Tromsø 4 and 5 measurements of number of plaques and total plaque area were 
associated with lower scores on all cognitive tests (p≤0.02) in Tromsø 5. Progression of 
both plaque number and total plaque area were independently associated with lower 
scores on the digit-symbol coding test (p≤0.04) and the tapping test (p≤0.03), but not on 
the verbal memory test. In the subgroup followed with cognitive retesting in Tromsø 6 




5.  Discussion 
5.1 Methodological considerations  
5.1.1 Study design 
The major strengths of this study are the large sample size, the prospective design, 
relevant adjustment variables and the use of repeated and standardized measurement 
of carotid ultrasound and cognitive tests sensitive to cognitive decline in a general 
population (52, 55). To our knowledge no other population-based studies have 
examined the progression of carotid atherosclerosis in relation to cognitive function.  
 
The study design also has some limitations.  We had no information of cognitive 
function at baseline, and could therefore not be certain of the temporal association 
between risk factors and cognitive test scores.  Nevertheless, the independent variables 
were assessed 7 years before cognitive testing, and this combined with knowledge from 
previous prospective studies, indicate that the risk factors are predictors of lower 
cognitive test scores and not the opposite (23, 31).  
 
The three cognitive tests used in this study were chosen for their feasibility in the 
setting of a large population study with a large number of participants who also went 
through a considerable number of other clinical and laboratory tests. The tests do not 
give a total picture of an individual’s cognitive function, and interpretation of results is 
restricted to the cognitive domains studied. The study did not include validated tests for 
dementia or MCI, and no validated cut-off limits for cognitive impairment existed for the 
cognitive tests used.  However, Mini-Mental State Examination (MMSE) was added to 
the cognitive test battery in Tromsø 6, but was not used in this study because no follow-
up data were available for this test. Outcome measures were cognitive test scores, 
either assessed as continuous variables or comparing scores in the lowest quintile with 
the other four.  A more comprehensive cognitive test battery with validated cut-off 
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limits for cognitive impairment or dementia would have strengthened the study and 
made clinical interpretations easier.   
 
Examination of only the right carotid artery may be a limitation, as inclusion of the left 
carotid artery might have given a better description of the individual total carotid 
plaque burden. The side of which carotid atherosclerosis occurs may affect cognitive 
tests results differently.  Previous epidemiological and clinical studies have found that 
left carotid stenosis, in contrast to stenosis on the right side, is more strongly associated 
with lower performance on cognitive tests involving language and on Modified MMSE  
(31, 56), and also with progression of AD assessed by MMSE (57). However, in Paper II 
we found that both high number of plaques and total plaque area at baseline were 
associated with lower scores on the verbal memory test after 7 years follow-up, and the 
average plaque scores between baseline and follow-up were associated with scores on 
all cognitive tests. MRI imaging of the cohort would have added valuable information to 
the interpretation of our results regarding the role of vascular mechanisms.   
 
 
5.1.2 Internal validity 
Selection bias 
High participation rates and no predefined selection criteria for invitation other than 
birth year and being a resident of the municipality of Tromsø, minimized the chance of 
selection bias in Tromsø 4-6. Detailed analyses of mortality or morbidity according to 
attendance have not been possible because of legal restrictions.  However, subjects who 
were consistent attendees demonstrated a lower mortality than subjects who attended 
only one of the surveys (47). Both the exposure (carotid atherosclerosis) and the 
outcome variables (cognitive test scores) may have been subject to selection bias.  
Participants with the most advanced atherosclerosis could be less likely to attend the 
follow-up studies due to cardiovascular disease or death.  We have no information on 
cognitive function of those who did not meet, but a selection towards lower 
32 
 
participation rate among persons with cognitive impairment and dementia both at 
baseline and at follow-up would be expected. Though invited, institutionalized persons 
were probably not able to appear at the location of the survey or to complete the 
comprehensive screening battery. Selection of subjects in the data collection process 
has probably occurred, as 561 more subjects completed the tapping test than the digit-
symbol coding test in Tromsø 5.  It is likely that the proportion of subjects with cognitive 
impairment was higher among those who did not complete all tests.  All these sources 
of selection bias have probably affected the overall rate of decline in cognitive test 
scores from Tromsø 5 to 6, as the average decline was approximately as could be 
expected as an effect of age alone (Table 1).  This may have precluded the possibility to 
find associations between risk factors and cognitive decline.     
 
Information bias and misclassification  
Information bias occurs when measurement of either the exposure or the outcome 
variables is systematically inaccurate.  In cohort studies, misclassification of exposure 
variables is often non-differential (not dependent of the outcome variable), and usually 
attenuates or underestimates the effect estimate.  The problem of information bias has 
been addressed in the Tromsø study in general by having test personnel that are not 
directly involved in the scientific project and thereby not biased by scientific hypothesis 
in their measurement. Standard protocols and standard operational procedures 
contributed to minimizing errors.  In this study, information on smoking, disease, use of 
medication and depression was obtained from self-administered questionnaires. Such 
information is likely to be inaccurate and a source of information bias (58).  In a previous 
validation study on self-reported stroke based on questionnaires from participants in 
Tromsø 4, the positive predictive value was 0.79, sensitivity 80% and specificity 99% 
(59). To avoid misclassification, we used the Tromsø study end-point registry for 
assessing strokes in Paper II and III and found more stroke cases than was self-reported.  
The sensitivity of self-reported diabetes is found to be moderate in other studies (60, 
61). To increase sensitivity, diabetes was defined as self-reported diabetes and/or 
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regular use of insulin or oral antidiabetics.  We used current daily smoking as a predictor 
in this study, as data on previous smoking habits are prone to recall bias and did not add 
any new information to the analyses.  Previous studies on the serum concentration of 
thiocyanate in smokers and non-smokers have supported the validity of the responses 
to the question on smoking (62, 63). Answers to the questions regarding physical 
activity were in a previous study found to have an inverse dose-response relationship 
with BMI and smoking (64).  Assessment of depression could have been more accurate if 
we had used a standardized depression scale (for example MADRS). Blood samples were 
of practical reasons assessed non-fasting.  Regarding total-cholesterol, fasting or eating 
before blood collection does not have a marked effect on measurements (65).  
 
Reproducibility of ultrasound measurements was found to be acceptable (34, 49, 50).  In 
Paper III we found that the average measurement of plaque scores in Tromsø 4 and 5 
was associated with lower scores on all cognitive tests, whereas baseline plaque scores 
or the change in plaque scores were not consistently associated with all tests.  An 
alignment of measurements errors with use of the average plaque scores could make 
the average scores a more robust exposure variable.   
 
Confounding 
A confounder is an independent risk factor for the outcome variable that is also 
associated with one or more of the exposure variables of interest.  Confounding could 
lead to under- or overestimation of the association studied.  We adjusted for known 
confounders such as sex, age, education, depression and vascular risk factors.  We did 
not measure the APOE gene, where the ε4 allele has been found to be a major risk 
factor for AD.  The presence of one copy of the APOE ε4 allele increases the risk of late-
onset AD by about three times and two copies by about 12 times, but presence of the 
APOE ε4 is neither necessary nor sufficient for developing the disease (66). Several 
studies have found an association between the ε4 allele and higher carotid IMT, and 
although significant results have not always been found (67), APOE ε4 may be a 
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confounder in the relationship between carotid atherosclerosis and cognitive test 
results.   
 
Excessive alcohol drinking is a risk factor for cognitive impairment, but some studies 
have found that low or moderate alcohol consumption, especially wine consumption, 
may protect against cognitive decline (68, 69).  In a previous paper from the Tromsø 
study, we found that moderate wine consumption was independently associated with 
lower cognitive test scores after 7 years follow-up (70). Moderate alcohol consumption 
may also lower the risk of atherosclerosis (71) and be a possible confounder for the 
relationship between atherosclerosis and cognitive test results.  Adjustment for alcohol 
consumption in our study did not change estimates of the association between 
atherosclerosis and cognitive test scores and were therefore not included in analyzes.    
 
5.1.3 External validity 
External validity refers to the generalizability of results and applicability  to other 
populations.  Selection criteria for participation in the Tromsø study were age and 
residency in Tromsø, and the Population Registry of Norway was the source for the 
invitations.  All age groups of interest were studied and the risk factor levels of the 
Tromsø population are compareable to other Western populations.  Our results are 
therefore probably applicable to other Western populations, however, generalizability 
could be restricted by ethnicity, as the Tromsø population mainly are Caucasians. 
Associations between vascular risk factor, atherosclerosis and cognitive test scores are 
restricted to the cognitive domains studied.   
 
5.1.4 Statistical considerations 
Although we found statistically significant predictors of cognitive test results the 
magnitude of the effects observed were probably modest. Estimation of the statistical 
power needed for showing a possible clinical relevant difference or change in cognitive 
test scores was not possible because no validated cut-off limits for the cognitive test 
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scores existed.  In Paper I, we divided cognitive test scores in quintiles to estimate risk 
difference between participants scoring in the lowest quintile compared to the upper 
four, but we don’t know if this cut-off represents a clinical meaningful limit.   
 
 
5.2 Discussion of main results 
5.2.1 Cardiovascular risk factors and cognitive test results 
Diabetes, smoking, and systolic blood pressure were independent predictors for lower 
cognitive performance after 7 years of follow-up in both men and women, and 
physically active women had lower risk of low cognitive test scores.  
 
Diabetes showed the strongest negative relationship to cognitive test scores in both 
genders with a 3 fold increased OR of scoring in the lowest quintile on the verbal 
memory test in men, and a 2 fold increased OR on the tapping and digit-symbol coding 
tests in women. This is in line with observations from previous population-based studies 
(23, 42, 72).   
 
Whereas some earlier studies found no association and even positive associations 
between smoking and cognitive function (23), recent prospective studies have found 
negative associations between smoking and cognitive function (73). This is supported by 
our study. The negative effect of smoking may be more pronounced in those not 
carrying the APOE ε4 allele (74).  
 
Systolic blood pressure was negatively associated with cognitive performance and 
hypertensive women had an increased risk of lower cognitive test scores.  This is in line 
with some previous cohort studies (23).  Other studies found no association (75), and 
some have indicated a U-shaped association between blood pressure and cognitive 
function (76). Methodological differences between studies, such as the age at 
assessment of blood pressure and of cognitive function, different cognitive domains 
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studied and the length of follow up, may be some of the reasons for the conflicting 
results (77, 78).  A recent  Cochrane review of  four randomized controlled trials on 
blood pressure treatment in prevention of cognitive impairment and dementia showed 
no overall benefit of treatment (79).  The high average age of 75.4 years of participants 
and the relatively short mean follow-up time of 5 years in these studies may have 
caused the negative results. While the impact of late-life hypertension is unclear and 
even may be a result of cognitive decline, several studies have shown that mid-life 
hypertension is a risk factor for cognitive decline in late life (78, 80). 
 
Previous studies on the relationship between physical activity and cognitive function are 
conflicting. Reduced risk of dementia was found in a 21 years follow-up study in physical 
active men and women (81). In a 5-year follow-up study of 4615 men and women aged 
65 and above, physical activity protected against cognitive impairment and Alzheimer’s 
disease only in women (82). Other studies have found no association between physical 
activity and cognitive function (83).  Physical activity may prevent vascular damage and 
protect against cognitive decline through a number of possible mechanisms. Physical 
activity reduces blood pressure, cholesterol level, BMI and prevents development of 
diabetes. Influence on brain plasticity, angiogenesis, synaptogenesis, neurogenesis, and 
increased levels of neurotrophic factors may also play a role in the association of 
physical activity and cognitive function (84). Exercise is found to significantly reduce the 
amount of amyloid-β (Aβ) plaques in transgenic mice (85). The results of our study may 
indicate a better preventive effect of physical activity on cognitive testing in women 
than in men.  Interactions between exercise and hormone metabolism might contribute 
to sex differences.  However, the effects are small with partly overlapping confidence 
intervals between genders and should be interpreted with caution.   
 
No association was found between serum total-cholesterol, HDL-cholesterol or coronary 
heart disease and cognitive test scores in any of the regression models. The lack of 
association between cholesterol and cognitive function is surprising given the strong 
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association between cholesterol and large vessel atherosclerosis which can increase the 
risk of vascular dementia. Furthermore, cholesterol reduces amyloid precursor protein 
alpha, increases cerebral β-amyloid peptide generation and could thereby increase the 
risk of AD (86).  Some cohort studies of ageing populations found no effect (23) and 
even protective effects of cholesterol (87), but a study on 40-45 years old subjects found 
that increasing cholesterol levels increased the risk of both vascular dementia and AD 
three decades later (88).  In two reviews, total-cholesterol measured in mid-life, but not 
in late life where a risk factor for dementia (89, 90). Randomized controlled trials on 
treatment of cholesterol with statins in the prevention of dementia or cognitive decline 
with  3-5 years follow-up were negative (86). The negative results in these studies may 
have been influenced by the relative short period of follow-up. The lack of association 
found for lipids in contrast to associations found for diabetes and hypertension in our 
study, may be due to a greater effect of small vessel, rather than large vessel disease on 
early cognitive impairment.  Small vessel disease could particularly affect subcortical 
circuitry and thereby executive function which can be revealed by impaired digit-symbol 
coding test scores.  MRI manifestations of cerebral small vessel disease are thought to 
develop gradually from white matter lesions (WML) to leucoaraiosis and lacunar 
infarcts.  WML have been found to increase the risk of dementia (91, 92).   
 
At the time when Paper I was written, data on cognitive test scores in Tromsø 6 and 
cognitive decline from Tromsø 5 to 6 were not ready.  In supplementary analyses made 
when data on cognitive decline was available, no consistent associations were found 
between baseline vascular risk factors and cognitive decline in multivariabel regression 
analyzes adjusted for sex, age, education, depression, systolic blood pressure, total-
cholesterol, HDL-cholesterol, body mass index, current smoking, physical activity, 
diabetes and coronary heart disease in 2467 subjects with complete baseline data of 
vascular risk factors and data on cognitive decline from 7 to 13 years of follow-up. Age 
was a consistent predictor of cognitive decline on the digit symbol coding test and the 
tapping test.  Subgroup analyses of those in the highest quartile of decline did not add 
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new information (data not shown). Selection bias may have precluded our possibility to 
detect associations between vascular risk factors and cognitive decline, as discussed in 
the chapter of internal validity on page 32. 
 
5.2.2 Carotid atherosclerosis and cognitive test results 
In Paper II, the mean total IMT at baseline predicted lower score on the coding test after 
7 years of follow-up, but as plaques were included in our IMT measurements, the 
association between mean total IMT and cognitive test scores is probably largely 
dependent on plaque formation. The lack of association with CCA-FW-IMT further 
underlines this, as plaques are infrequent in this segment.  
 
The presence of carotid atherosclerotic plaques at baseline predicted lower scores on 
the verbal memory test and the digit-symbol coding test after 7 years of follow-up, but 
baseline scores of the number of plaques and the total plaque area only predicted lower 
scores on the verbal memory test. In paper III we found that the average plaque scores 
of measurements at baseline and 7 years follow-up were associated with lower scores 
on all cognitive tests. Progression of plaque scores was associated with lower scores on 
digit-symbol coding test and tapping test.   Thus, average plaque scores may seem like 
better predictors for cognitive test results than change in plaque scores or baseline 
plaque scores. This could be due to measurement errors in assessing a one-time 
measurement or change in measurements, whereas an average score may align these 
errors.  
 
Progression of total plaque area and plaque number was not associated with lower 
scores on the verbal memory test. As noted previously in the discussion of study design, 
carotid atherosclerosis in the left carotid artery is more strongly associated with lower 
performance on cognitive tests involving language (56), and this could be one reason 
why no association was found. However, the average plaque scores between baseline 




In supplementary analyses of average plaque scores and progression of plaque scores 
from baseline to 7 years of follow-up and cognitive test results after 13 years of follow-
up in 2081 subjects, the estimates of the effect of plaque scores on cognitive test result 
did not considerably differ from those found at 7 years of follow-up.  Significant results 
were found for the association between average plaque scores and scores on the verbal 
memory test and the digit-symbol coding test, but not for the other analyses, probably 
reflecting less power to detect significant associations in this cohort than in the cohort 
tested at Tromsø 5.      
 
We found no association between carotid atherosclerosis and cognitive decline. This 
apparent inconsistency could be due to several factors. The large loss to follow-up on 
cognitive testing in Tromsø 6 makes interpretations of results on cognitive decline 
difficult. Selection bias has probably occurred as those with poor cognitive function 
either did not attend Tromsø 6 or could not complete all cognitive tests.  Those with 
repeated cognitive testing were younger and had a better vascular risk factor profile 
than those who only attended cognitive testing in Tromsø 5 (Table 1 in Paper III).  The 
prevalence of cognitive decline and dementia increases mainly from the age of 70, 
which was the mean age at the second cognitive testing, and may explain why cognitive 
decline were modest also in those who participated (3). A 7-8% decline in test scores on 
the verbal memory test and the tapping test was found, but this is not much more than 
the expected effect of aging (Table 1). The decline observed in scores on the digit-
symbol coding test was less than expected, and could be caused by measurement 
errors.  Larger within-person variance of repeated measurements than of single 
measurement of both atherosclerosis and cognitive tests can be expected to result in 
stronger estimates for single measurement analyses compared to measurement of 
progression.  Lower statistical power in the smaller subgroup with cognitive retesting 
combined with modest effects of carotid atherosclerosis on cognitive test scores may 




No other population-based studies have examined the progression of carotid plaques in 
relation to cognitive test results. The associations found between both the average of 
Tromsø 4 and 5 carotid plaque scores and progression of carotid plaque scores and 
lower cognitive test results in Tromsø 5 are in line with results from some previous 
epidemiological studies that have assessed the impact of a one-time measure of 
atherosclerosis on cognitive function. One cross-sectional study found that subjects with 
carotid stenosis (≥ 35%) performed weaker on cognitive tests than subjects without 
stenosis (43).  In a large cohort study, a high-grade stenosis (≥75%) in the left carotid 
artery at baseline was a significant predictor of cognitive decline. The results were 
independent of vascular changes on brain MRI (31). Several population-based studies of 
elderly subjects (>65 year) have found associations between carotid IMT in the CCA and 
ICA and subsequent cognitive decline (41, 42), but conflicting results were found in 
middle-aged populations. Two large cohort studies found no association between 
baseline mean carotid IMT and cognitive decline after 6 and 14 years of follow-up (23, 
44), whereas one study found  that mean carotid IMT at baseline was associated with 
poorer cognitive test performance after 4-years, independent of MRI markers of silent 
cerebral infarcts or white matter hyperintensities (32). Our findings add to the results 
from the last study, indicating that atherosclerosis in middle age is a risk factor for lower 
cognitive function in later life.  
 
In the Rotterdam study, the number of carotid plaques was associated with dementia in 
cross-sectional analysis (22), but this could not be confirmed in a later prospective study 
(46). However, a significant negative trend was found between number of carotid 
plaques and a combined endpoint of dementia and mortality, suggesting that higher 
mortality rate in subjects with carotid plaques may have attenuated a possible 
association between plaque number and dementia. The risk of AD was increased in the 
highest quintile of CCA-IMT compared with the lowest quintile (hazard ratio 1.54, 95% CI 
1.03-2.30) after 9 years follow-up in 5399 subjects, but carotid plaque number at 
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baseline did not predict dementia (46). Similar results were found in the Cardiovascular 
Health Study (CHS) were the highest quartile of baseline IMT in the CCA and ICA, but not 
carotid stenosis, was associated with increased risk of AD (45). One clinical study of 66 
patients with AD found that the progression of carotid plaques over 12 months 
correlated with increased cognitive impairment (93). 
 
Several possible mechanisms may explain an association between carotid 
atherosclerosis and lower cognitive test scores. Individuals with a confirmed stroke were 
excluded in this study, but embolisms from carotid atherosclerosis could cause silent 
strokes. Results from the population-based Rotterdam Scan Study showed that the 
presence of silent brain infarcts on MRI more than doubled the risk of dementia after 
3.6 years follow-up (94). Carotid atherosclerosis may also act as a marker of 
intracerebral atherosclerosis, cerebral small vessel disease, or microangiopathy with 
reduced intracerebral perfusion as a result.   Small vessel disease and MRI detectable 
white matter lesions have been associated with cognitive decline (91). However, three 
population-based studies found significant associations between carotid stenosis and 
reduced cognitive function independently of lesions detected on brain MRI (31, 32, 43). 
Theoretically, neuropsychological test results could be more sensitive to microembolic 
lesions than MRI. Cerebral hypoperfusion due to high-grade stenosis (>70%) could be a 
possible mechanism for lower cognitive scoring, but as the prevalence of high-grade 
stenosis in the general population is low, this is an unlikely explanation in our study (95). 
 
In addition to the possible effect of carotid atherosclerosis on silent ischemic cerebral 
lesions, the association between carotid atherosclerosis and cognitive test results could 
be mediated through AD pathology, as cases with mild cognitive impairment due to 
preclinical and early AD probably were included in the cohort. The association between 
carotid intima-media thickening and AD found in two studies (45, 46) may reflect two 
independent pathological processes that share the same risk factors such as high blood 
pressure and smoking (96), or that vascular changes play a role in the pathogenesis of 
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the disease (26). In the Rotterdam study, adjustment for cardiovascular risk factors did 
not attenuate the association between IMT and AD (46). Two large autopsy studies 
found no association between cerebral vascular lesions and the two hallmarks of AD, 
amyloid plaques and neurofibrillary tangles in individuals with AD, indicating no 
causative but maybe an additive effect of vascular lesions on AD  (97, 98). Three large 
autopsy studies found a strong association between the degree of intracranial 
atherosclerosis and Alzheimer pathology (17, 98, 99), whereas one study found no 
association (100). Low ankle-arm index was significantly associated with increased risk 
of AD, indicating that generalized atherosclerosis could be a risk factor for AD (45). The 
mechanisms for a possible associations between atherosclerosis and AD are still unclear, 
but cerebral hypoxia could possibly destabilize neurons and contribute to a 
neurodegenerative process characterized by formation of neurofibrillary tangles and 
amyloid plaques (26).   
     
     
6. Conclusions and implications for further research  
We found that diabetes, smoking, hypertension, physical inactivity and the presence of 
carotid plaques at baseline predicted lower scores on cognitive tests after 7 years of 
follow-up.   Progression of plaque scores from baseline to 7 years of follow-up was 
associated with lower scores on cognitive tests at follow-up.  No associations were seen 
between vascular risk factors, carotid atherosclerosis and cognitive decline.  
 
Results from this study suggest that diabetes, smoking, hypertension, physical inactivity 
and carotid atherosclerosis could be targets for preventive efforts to delay cognitive 
impairment, but as no associations were found between risk factors and cognitive 
decline, interpretations should be made with cautiousness.    
 
Effect estimates from other epidemiological studies indicate that modification of 
vascular risk factors could have a great impact on prevention of dementia (101), and 
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clinical studies have found that intensive treatment of vascular risk factor could delay 
progression of atherosclerosis (35, 102). However, intervention studies on blood 
pressure and lipid lowering treatment in the prevention of dementia and cognitive 
impairment have so far been disappointing (79, 86). Negative results in intervention 
studies may have been caused by small sample size, short periods of follow-up, and that 
study-subjects already were in a prodromal phase of dementia and had passed the time-
window for prevention (103, 104).   
 
There is a need for future studies with long time follow-up to further explore how 
vascular risk factors and atherosclerosis affects the risk of cognitive impairment and 
decline.  We need more knowledge about how the length of exposure and the age at 
exposure to risk factors affect cognitive decline, and whether an optimal time-window 
for preventive strategies exists.  Little is also known about whether cut-off levels exist 
for when risk factors affects cognitive decline and if relations are linear or not.  
Population studies that assess how medications used for treating vascular risk factors 
and atherosclerosis affect cognitive decline could give valuable information for 
designing new intervention studies.  To further explore the pathophysiological 
mechanisms of how atherosclerosis and vascular risk factors affects cognitive function, 
brain MRI and genetic testing of APOE should be included in the test battery.    
 
A major concern in the interpretation of our study was the great loss to follow-up from 
Tromsø 5 to 6 and the lack of cut-off values for clinically important low scores on the 
cognitive tests.  In future studies, the cognitive tests should be validated against criteria 
for mild cognitive impairment.  The problem of loss to follow-up could partly be solved 
by ambulatory screening procedures in the homes of participants or at nursing homes.  
However, ethical aspects of such recruitment strategies would need careful 
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Appendix  A 
 
Questionnaire 1 
Tromsø 4, 1994-95 
English version 
 
      The Health Survey is coming to Tromsø. 
This leaflet will tell you when and where. You will 
also find information about the survey in the enclosed 
brochure. 
     We would like you to fill in the form overleaf and 
take it with you to the examination. 
    The more people take part in the survey, the more 
valuable its results will be. We hope, therefore, that 
you will be able to come. Attend even if you feel 
healthy, if you are currently receiving medical 
treatment, or if you have had your cholesterol and 
blood pressure measured recently. 
Yours sincerely, 
Municipal Health Authorities 
Faculty of Medicine - University of Tromsø 
National Health Screening Service 
 Electoral ward No. Municipality  Social security No.Date of birth     
HEALTH SURVEY 
Invitation                                                                  
   
Welcome to the Tromsø Health Survey!                 
“THIS IS YOUR
       CHANCE”
“THIS IS A REAL 
OPPORTUNITY- TAKE IT!”
 What is your current state of health? 
 Do you have, or have you had: 
 Do you use blood pressure lowering drugs? 
Have you during the last year suffered from pains 
and/or stiffness in muscles and joints that have 
lasted continuously for at least 3 months? 
 Have you in the last two weeks felt: 
How has your physical activity in leisure time been during this 
last year? 
How many cups of coffee do you drink daily?      
Are you a teetotaller?                        
How many times a month do you normally drink      
alcohol?        
 Did any of the adults at home smoke while 
you were growing up? 
 Do you currently, or did you previously, live together
 with daily  smokers after your 20th birthday? 
 If "YES", for how many years in all? .............
 How many hours a day do you normally spend 
in smoke-filled rooms? .....
Do you yourself smoke: 
If you previously smoked daily, how long 
is it since you quit?.........................................
If you currently smoke, or have smoked     
previously:       
How many glasses of beer, wine or spirits do you        
normally drink in a fortnight?
What type of margarine or butter do you usually use on     
bread?     
What is the highest level of education you have completed?
What is your current work situation?           
How many hours of paid work do you have per 
week? 
Do you receive any of the following benefits? 
Have one or more of your parents or      
siblings  had a heart attack or had
angina (heart cramp)? ..............................
          
    
Tick one box only. 
Poor  




Angina pectoris (heart cramp)   













 Put 0 if you do not spend time in smoke-filled rooms. 
Cigarettes daily?    
Cigars/ cigarillos daily?    
A pipe daily?
How many cigarettes do you or did you  
usually smoke per day?    
How old were you when you began  
daily smoking?
How many years in all have you smoked  
daily?   
Think of your weekly average for the year. 
Time spent going to work counts as leisure time. 
Light activity (not       
sweating/out of breath)  
Hard activity (sweating/
out of breath) ..........
Coarsely ground coffee for brewing
Other coffee
Hours per week
None    Less than 1 1-2   3 or more
Put 0 if you do not drink coffee daily.     
Put 0 if less than once a month.  .....
Do not count low-alcohol beer. 
Tick one box only. 
Do not count low-alcohol beer. 
Put 0 if less than once a month. 
Don't use butter/margarine 
Butter .............
Hard margarine 
Soft margarine ....... 
Butter/margarine mixtures
Light margarine  
7-10 years primary/secondary school,          
modern secondary school
Technical school, middle school, vocational   
school, 1-2 years senior high school 
High school diploma                                       
(3-4 years)........................




Unemployed, on leave without payment
Sickness benefit (sick leave) 






   Cups      
   Cups      
    Times  
Glasses Glasses Glasses 
Beer Wine 
 
  Spirits    
 No. of     
hours  
   Years   
cigarettes
Age
        years
   Years   
   Years   
   Hours   
 Age first       






Yes No Don't know
No  A little
  
   A lot 
  Very 
  much




EDUCATION/WORK            SMOKING








Appendix  B 
 
Questionnaire 2 (<70 years)                
Tromsø 4, 1994-95 
English version 
 
    The main aim of the Tromsø Study is to improve our 
knowledge about cardiovascular diseases in order to aid 
prevention. The survey is also intended to improve our 
knowledge of cancer and other general conditions, such as 
allergies, muscle pains and mental conditions.  We would 
therefore like you to answer some questions about factors 
that may be relevant for your risk of getting these and other 
illnesses. 
   This form is a part of the Health Survey, which has been 
approved by the Norwegian Data Inspectorate and the 
Regional Board of Research Ethics. The answers will only 
be used for research purposes and will be treated in strict 
confidence. The information you give us may later be stored 
along with information from other public health registers in 
accordance with the rules laid down by the Data Inspectorate 
and the Regional Board of Research Ethics. 
  If you are in doubt about what to answer, tick the box that 
you feel fits best. 
  The completed form should be sent to us in the enclosed 
pre-paid envelope. 
Thank you in advance for helping us. 
Yours sincerely, 
Faculty of Medicine  National Health 
University of Tromsø Screening Service
 
If you do not wish to answer the questionnaire, tick the 
box below and return the form. Then you will not receive 
reminders. 
I do not wish to answer the questionnaire ..................................
 Date for filling in this form:................................
 Day  Month  Year
In which Norwegian municipality did you live  at the age of 1 year? 
If you did not live in Norway, give country of residence instead of municipality.
How was your family's financial situation during your 
childhood? 
Very good ..............................................................
How many of the first three years of your life   
How many of the first 15 years of your life                  
 Who do you live with?                
Good ........................................................................
Difficult .....................................................................
Very difficult  .............................................................
 - did you live in a town/city? .......................................
 - did your family have a cat or dog in the home? .......
 - did you live in a town/city? .......................................





Yes No  
Yes No  
Yes No  
Yes No  
Yes  No   Tick once for each item and give the number .       
 Spouse/partner ............................................
 Other people over 18 years .........................
 People under 18 years ................................
How many of the children attend day care/kindergarten? ....




Terraced /semi-detached house ........................
Other ..................................................................
 How big is your house? ..................................................
 Approximately what year was your house built? ............
 Has your house been insulated after 1970?...............
 Do you live on the lower ground floor/basement? .....
 If "Yes", is the floor laid on concrete? ...................
What is the main source of heat in your home?   
Number   
Electric heating ......................................................
Wood-burning stove .................................................
Central heating system using:                  
Paraffin ...................................................................
Electricity ................................................................
Do you have fitted carpets in the living room? ............
Is there a cat in your home? .......................................
Is there a dog in your home? ......................................
If you have paid or unpaid work, how would you describe   
 your work? 
Mostly sedentary work? .........................................
(e.g. office work, mounting) 
Work that requires a lot of walking? ..........................
(e.g. shop assistant, light industrial work, teaching)  
Work that requires a lot of walking and lifting? ..........
(e.g. postman, nursing, construction) 
Heavy manual work? .................................................
(e.g. forestry, heavy  farm-work, heavy construction) 
Can you decide yourself how your work should be         
organised? 
No, not at all ..........................................................
To a small extent ......................................................
 Who do you live with?   Yes, to a large extent ................................................
Are you on call, do you work shifts or nights?.............
Do you do any of the following jobs (full- or part-time)?




Yes, I decide myself ..................................................
       HOME   
      WORK
CHILDHOOD/YOUTH
The Tromsø Health Survey                            
   ILLNESS IN THE FAMILY  
   USE OF HEALTH SERVICES   
YOUR OWN ILLNESSES        SYMPTOMS      
Do you cough about daily for some periods of the year?
Have you ever had: 
Tick one box only for each item. Give your age at the time. 








Have you you ever had, or do you still have: 







Fibromyalgia/fibrositis/chronic pain syndrome .........





Allergy and hypersensitivity: 




Other hypersensitivity (not allergy) ....................
How many times have you had a cold, influenza (flu),
vomiting/diarrhoea, or similar in the last six months? 
Have you had this in the last 14 days?.......................
Tick for the relatives who have or have ever
had any of the following diseases: 
Tick "None" if none of your relatives have had the disease.               
Cerebral stroke or brain haemorrhage








age when they got
diabetes ..................................
If "Yes":     
Is your cough productive ? ..............................
Have you had this kind of cough for as long as
3 months in each of the last two years? ............
Have you had episodes of wheezing in your chest?
If "Yes", has this occurred:      
Tick one box only for each item.     
At night ................................................................
In connection with respiratory infections ..................
In connection with physical exertion ........................
In connection with very cold weather .......................
Have you noticed sudden changes in your pulse 
or heart rhythm in the last year?.................................
How often do you suffer from sleeplessness? 
Never, or just a few times a year .........................
1-2 times a month .....................................................
Approximately once a week ......................................
More than once a week .............................................
If you suffer from sleeplessness, what time       
of the year does it affect you most? 
No particular time of year ...................................
Especially during the polar night .............................
Especially during the midnight sun season .............
Especially in spring and autumn ..............................
Have you in the last year suffered from sleeplessness
to the extent that it has affected your ability to work?...
How often do you suffer from headaches? 
Rarely or never .....................................................
Once or more a month ...............................................
Once or more  a week ...............................................
Daily ...........................................................................
Does the thought of getting a serious illness ever 
worry you? 
Not at all ...............................................................
Only a little ................................................................
Some .........................................................................
Very much .................................................................
How many visits have you made during the past year 
due to your own health or illness:
Tick 0 if you have not had such contact 
To a general practitioner (GP)/Emergency GP ............
To a psychologist or psychiatrist .....................................
To an other medical specialist (not at a hospital) ............
To a hospital out-patient clinic .....................................
Admitted to a hospital ......................................................
To a medical officer at work .............................................
To a physiotherapist ....................................................
To a chiropractor .............................................................
To an acupuncturist .........................................................
To a dentist ..................................................................
To an alternative practitioner (homoeopath, foot zone therapist, etc.) 
To a healer, faith healer, clairvoyant  ..............................
Number of times 
the past year
Yes  No  
Yes  No  
Yes  No  
Yes  No  
Yes  No  
Age    
times     
Mother Father Brother Sister Child None  
Gastric/duodenal ulcer surgery ....................
MEDICATION AND DIETARY SUPPLEMENTS            FOOD HABITS           
       FRIENDS      
Have you for any length of time in the past year used any of the 
following medicines or dietary supplements daily or almost daily? 
Indicate how many months you have used them. 
Put 0 for items you have not used. 
Medicines
Painkillers ............................................................







Dietary supplements            
Iron tablets ...........................................................
Calcium tablets or bonemeal ...................................
Vitamin D supplements ............................................
Other vitamin supplements ..................................
Cod liver oil or fish oil capsules ...............................
Have you in the last 14 days used the following             
medicines  or dietary supplements? 
Tick one box only for each item. 
Medicines            
months
good
friends    
Painkillers           .............................................................
Antipyretic drugs (to reduce fever) ...........................
Migraine drugs .........................................................
Eczema cream/ointment ..........................................
Heart medicines (not blood pressure) ......................




Other drugs for nervous conditions ..........................
Antacids ...............................................................
Gastric ulcer drugs ...................................................
Insulin .......................................................................
Diabetes tablets ........................................................





Calcium tablets or bonemeal ...................................
Vitamin D supplements ............................................
Other vitamin supplements ..................................
Cod liver oil or fish oil capsules ................................
- jam and other sweet spreads .......
confidentially with and who give you help when you need it? 259
Do not count people you live with, 
but do include other relatives!  
How many of these good friends do you have 
contact with at least once a month? .........................
Do you feel you have enough good friends? ...........
How often do you normally take part in organised   
gatherings, e.g. sewing circles, sports clubs, 
political meetings, religious or other associations?     
Never, or just a few times a year .........................
1-2 times a month ....................................................
Approximately once a week .....................................
More than once a week ............................................ Waffles, cakes, etc. ..................
Chocolate .......................................
Sugar-free ("Light") soft drinks .....








- lean fish (e.g. cod)  ....................
- fatty fish (e.g. salmon/redfish)
- sausage/meatloaf/ meatballs .....
Dinner with
- unprocessed meat......................
Breakfast cereal/ oat meal, etc. ...
Boiled or fried egg ........................
Yoghurt ....................................
How many times per week do you normally eat the following foodstuffs? 
How many good friends do you have whom you can talk
What kind of fat is normally used in cooking         
(not on the bread) in your home? 
A catering portion is enough for about
If you use butter or margarine on your bread, how many slices does   
a small catering portion normally cover? By this, we mean the 






Tick one or two boxes! 
The bread I eat is most similar to:
Sleeping pills 
How much (in number of glasses, cups, potatoes or slices) do you   
usually eat or drink daily of the following foodstuffs? 
Tick one box for each foodstuff. 
Full milk (ordinary or curdled) (glasses)
Semi-skimmed milk .........................
(ordinary or curdled) (glasses)
Tea (cups) .......................................
Orange juice (glasses) ....................
Potatoes .....................................
Slices of bread in total 
(incl. crisp-bread) ............................
Slices of bread with 
- fish 
(e.g. mackerel in tomato sauce) .....
- lean meat                    
(e.g. ham) .......................................
- fat meat                       
(e.g. salami) ....................................
- cheese (e.g. Gouda/ Norvegia) .........
- brown cheese ...............................







  Coarse 
brown  
   Crisp 
  bread 
Skimmed milk (ordinary or curdled) (glasses)
Tick a box for all foodstuffs listed. 
slices   
 Less 
 than 1 
 More 
than 6 
  Never 
 Less 
 than 1 
  almost  
daily 










What kind of bread (bought or hom -made) do you usually eat?         
      ALCOHOL
How often do you usually drink   
Never, or just a few times a year .......
1-2 times a month ..............................
About once a week ............................
2-3 times a week ...............................
More or less daily ..............................
Approximately how often during the last year have you consumed 
alcohol corresponding to at least 5 small bottles of beer, a bottle 
of wine, or 1/4 bottle of spirits?            
Not at all the last year ...............................................
A few times ...............................................................
1-2 times a month .....................................................
1-2 times a week ......................................................
3 or more times a week ............................................
For approximately how many years has your alcohol       
consumption been as you described above? ..................
- before age 20 ..................................................
years
   spirits?   wine?beer?
 TO BE ANSWERED BY WOMEN ONLY 
      MENSTRUATION   
      PREGNANCY     
      WEIGHT REDUCTION   
      URINARY INCONTINENCE       
      CONTRACEPTION AND ESTROGEN  
- later .................................................................
If you have lost weight deliberately, about how many                 
kilos have you ever lost at the most? 
- before age 20 ..............................................................
- later .............................................................................
What weight would you be satisfied with 
(your "ideal weight")? ....................................................
How often do you suffer from urinary incontinence?
Never ...................................................................
Not more than once a month ...................................
Two or more times a month .....................................
Once a week or more ..............................................
Your comments:            
Do you use, or have you ever used: 
Oral contraceptive pills (incl. minipill) ...
Hormonal intrauterine device ....................
Estrogen (tablets or patches) ..............
Estrogen (cream or suppositories) ............
If you use oral contraceptive pills, hormonal intrauterine device,                 
or estrogen, what brand do you currently use? 
If you use or have ever used oral contraceptive pills: 
How many years in total have you taken the pill? .....
If you have given birth, how many years did you 
take the pill before your first delivery? .......................
If you have stopped taking the pill: 
       Age when you stopped? .....................................
Thank you for the help! Remember to mail the form today! 
The Tromsø Health Survey 
How old were you when you started                       
menstruating? ................................................................
If you no longer menstruate, how old were
you when you stopped menstruating? ...........................
you ever stopped having menstruation for      
6 months or more? ...................................................
If "Yes", how many times? ..................................
If you still menstruate or are pregnant:                         
What date did your last menstruation period begin?
Do you usually use painkillers to                       
relieve period pains? ............................................
How many children have you given birth to? .............
Are you pregnant at the moment? ....................
Have you during pregnancy had 
high blood pressure and/or proteinuria? ...........
If "Yes", during which pregnancy? 
High blood pressure ....................................
Proteinuria ...................................................
If you have given birth, fill in for each child the year of birth 
and approximately how many months you breastfed the child. 
Child Year of birth:  
About how many times have you deliberately tried to 
lose weight? Write 0 if you never have. 
Apart from pregnancy and after giving birth, have        
Yes  No 
day/month/year
 times  
  No Yes 
years
years
Number of months 
breastfed:
Yes  No 
Yes  No 
 children  
 Don't know  
 Pregnancy
First         Later  
Age when you started to take the pill? ......................
  times  





  times  
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Appendix  E 
 
Protocol for ultrasound 
measurements  





PROCEDURES FOR MEASUREMENTS OF INTIMA-MEDIA THICKNESS AND 
RECORDING AND MEASUREMENTS OF PLAQUE OF THE RIGHT CAROTID 
ARTERY.  THE TROMSØ-STUDY 1994/95 AND 2001  
 
by Oddmund Joakimsen 




1. The Acuson ultrasound instrument is switched on. 
 
2. A videocassette is inserted in the video recorder. 
 
3. Check that the videotape has been wound to the right position, do not overwrite previous 
recordings. The videocassette should not be removed from the recorder during the day. 
    
4. Cassettes are marked with serial numbers, uneven numbers for Acuson I, even numbers for 
Acuson II.  
 
5. The initials and the identity numbers of the participant and the sonographer number (Einar 
= 1, Stein Harald = 2, Technician = 3) are written on each ultrasound image recorded. 
Labels with the ID-number of the participants are attached to the registration form, in 
which all ultrasound data obtained from the participants are filled (plaque localization, 
size, “missing measures” coding, etc.). 
 
6. A RES-field, appropriately adjusted to a maximum width of the screen and a depth of a 
little more than the preset size (> 2 cm) is positioned on the screen (This makes off-line 
calibration easier).  
 
7. The subject is examined in a supine position with the head slightly rotated to the left (15-
45 degrees). ECG-pads are attached to both arms and the right leg (or abdomen) (lead I), 
and the right carotid is insonated by a 7.5 MHz ultrasound transducer.  
 
8.  The examination starts with identification of crossectional B-mode images of the carotid 
artery, and, if necessary for identifying purposes in combination with colour-Doppler 
and/or pulsed wave Doppler 5 MHz. The examination starts caudally in the neck, normally 
just above the clavicle, then moving the probe upstream with simultaneous rotation 
movements to search for plaques also at the circumference of the vessel. Thus, the carotid 
artery is searched from the proximal part of the common carotid artery (CCA), upstream to 
the bifurcation (BULB), and as far up in the internal carotid artery (ICA) as technically 
possible. A PLAQUE is defined as a presumed atherosclerotic lesion of the intima layer of 
the vessel wall presenting a focal protrusion of more than 50% of the intima-media 
thickness (IMT) of the surrounding vessel wall, often with deviating echogenicity 
compared to other part of the artery wall. Whether a plaque is present or not is a decision 
taken by the sonographer during the examination. Live crossectional imaging of the whole 




9. An ultrasound examination sequence is then performed in the TRIPLEX -mode (i.e.,     
  combination of B-mode examination, pulsed wave Doppler, colour Doppler) 3-4 cm     
  proximally to the bifurcation and upstream 2-3 cm distally the bifurcation in the ICA.    
  The objective of this part of the examination is to look for stenotic areas along the artery   
  that causes hemodynamic disturbances. However, if plaques later during the B-mode  
  scanning procedure are found suspicious of a hemodynamic significant stenosis, a new  
  TRIPLEX examination is performed to re-evaluate the flow conditions. A LIVE    
  TRIPLEX-sequence of the relevant part of the carotid artery is recorded on the videotape   
  if a stenosis is suspected. 
 
10. B-mode longitudinal ultrasound scanning of the carotid artery is then performed. To get 
an optimal topographic reference, the examination is starting as proximally as possible in 
CCA. The probe is then moving upstream with simultaneous rotating movements to look 
for plaques in all segments, both the near and the far wall. If a plaque is found, a frozen 
image of the vessel-wall is taken – either directly by using the “FREEZE”- key, or by 
choosing on of the pictures from the cine-loop. It is important that the plaque is presented 
as distinctly as possible and after the guidelines according to elementary ultrasound 
principles such as vertical propagation of the ultrasound beam, presentation of the plaque 
in the full diameter of the vessel and not in chord, not cutting the plaque skew causing a 
falsely too large thickness of the plaque. To ensure the quality of plaque registration, 
some technical points may be of help: The plaque should be “attached” at its both ends to 
the typical double-lined intima-media structures visible on the B-mode image, and these 
double-lined structures should best be visible both in the near and the far wall at the same 
time. When the echogenicity obtained is as high as possible (as bright as possible), this is 
an indication that the ultrasound waves have cut the plaque optimally. An electronic 
calliper is put on the top of the plaque (at the interface between the surface of the plaque 
and the vessel lumen), and another calliper in the presumed transition zone between the 
media and the adventitia layer. The distance between the callipers is the thickness of the 
plaque, and that value is put on the registration form in the appropriate box. The B-mode 
image of the plaque is identified correctly by marking on the display what has been 
found, and where: PLAQUE ICA FW (a plaque in the far wall of the internal carotid 
artery), PLAQUE BULB NW (a plaque in the near wall of the bifurcation), etc. A short 
recording of approximately 5 sec. is videotaped. If more than one plaque is present at a 
site (e.g., in the far wall of ICA), the largest is chosen and recorded. 
 After identifying and recording of plaques, imaging procedures to get optimal 
measures of IMT from CCA and the BULB are performed. Optimal images are available 
when distinct double contours of the vessel wall typical for the intima-media complex can 
be seen. It is important that the longitudinal axis of the insonated vessel wall is 
perpendicular to the ultrasound beam direction. To avoid falsely too thick intima-media 
layer, the IMT should be measured in the full diameter of the artery and not in a chord. 
When satisfactory images are achieved, R-wave triggered IMT-registrations are recorded 
on a cine-loop containing more than 20 images. Afterwards, the images stored in the cine-
loop are scrutinized and 3 of most representative images, and each at least 10 images 
apart, are selected for recording on the videotape.  
 Regarding IMT measurements in the BULB, the start of the BULB is first identified 
and then marked with an arrow. This is the point where the parallel walls of the CCA are 
starting to diverge. If the probe throughout the recording process in the cine-loop has 
changed position, the placing of the arrow marker must be adjusted accordingly. It is 
important to underline that it is the sonographer who places the marker and not the off-
 3 
line reader of the IMT-measurements. The arrow setting has to be as precise as possible, 
particularly when a plaque is located in the border zone between BULB and CCA to 
avoid over-or underestimating of IMT.  
       The target site for IMT measurements of BULB is the 1 cm area from the start 
of the BULB and upstream, distally. If only a part of this distance is measurable, a 
recording may, however, be performed on this shorter distance if the live sequence shows 
that this part of the vessel wall is representative of the rest of the 1 cm area. This shorter, 
measurable distance is marked with an electronic star. The 3 chosen images are marked 
BULB1, BULB2 and BULB3 and recorded on the videotape.  If no measurable image is 
possible to obtain, an image from the BULB is still recorded and marked MB, i.e., 
“missing bulb”. IMT measurements from the near wall of the BULB are not performed. 
 
  
11. Then a B-mode scanning of the CCA is performed, starting at the BULB and downstream     
as far as possible. Registration and measurements of plaque are done in the same way as 
mentioned above. The images with plaques are marked PLAQUE CCA FW and 
PLAQUE CCA NW, video recording is performed of both the live sequence and the 
frozen, marked images. R-wave triggered CCA IMT-registrations are recorded and the 3 
optimal images are chosen from the cine-loop as described in paragraph 10. It is 
important to get representative images also from the near wall since IMT-measurements 
from the CCA-NW will be done off-line. The arrow-marker is placed in the same position 
as for the BULB measurements. The target site for IMT measurements of CCA is the 1 
cm area from the start of the BULB and 1 cm downstream, proximally. The three images 
chosen to be recorded are marked CCA1, CCA2 and CCA3. If no measurable image is 
possible to obtain, an image from the CCA is still recorded and marked MC (”missing 
CCA”). All measurements on the far wall refer to the so-called “leading edge” principle 
(or “upper demarcation line”). These structures are not being different in thickness when 
the emitted power (mW/cm2) or of the ultrasound instrument’s gain setting are changed 
(nor are biological different conditions of subjects examined). 
 Near wall measurements, however, are performed on ”far edge” principles, which 
means that IMT to some degree may be dependent on some of the technical conditions 
mentioned above (e.g., gain setting). Standardized examination conditions therefore are 
particularly important for the near wall measurements. It is, however, not possible, in 
technical terms, to obtain such ideal conditions because individually instrument adjusting 
alternatives always are more or less involved in processing optimal B-mode images. 
However, setting of functions such, as emitted power of ultrasound, preprocession, 
postprocession, gainsetting, etc. should be standardized as much as possible. Biologic 
inter-individual differences (obesity, position of the neck arteries, short or long necks, 
etc.) causing need of some different adjustments, however, are not possible to 
standardize. If the visibility of IMT and plaques is not optimal, the gainsetting (both the 
general and the segmental) should first be adjusted to improve the quality of the image. 
The gain should all the time be set high enough to identify soft, echolucent plaques but 
not too high to conceal small plaques due to “ultrasound noise”. Only as an exception, 
adjustments of the other functions should be done. 
   






12. Scoring of plaque-echogenicity. We aim at the highest echogenicity as possible since    
false too low echogenicity is a common problem due to several reasons: The plaque is cut 
too skew by the ultrasound beam, the longitudinal axis of the insonated vessel wall is not 
parallel to the ultrasound probe surface causing sub-optimal reflection of ultrasound 
energy (scattering), a far wall plaque is located within a ultrasound shadow from a 
calcified near wall plaque due to sub-optimal insonation angel. We therefore use the 
ultrasound signals from the media-adventitia interface as a reference of echogenicity to 
enhance precision on morphology scoring. This structure is easy to identify and is always 
presenting as high-echogenic, and is also localized close to the target, the atherosclerotic 
plaque. 
      In a 4-step scale from 1 to 4, the media-adventitia echogenicity and plaques of similar 
echogenicity is given a value of 4. On a grey-scale, such objects appear white or close to 
white. A plaque of grade 1 consequently reflects no or almost no ultrasound signals and 
appears black or dark grey on images. Flowing blood appearing black on ultrasound 
images is the reference structure on this end of the scale. Grade 2 and 3 represent 
intermediary echogenicity: grade 1, the plaque consisting of more echolucent than 
echogenic material (≤ 50% echogenic material); grade 3, more echogenic than echolucent 
(> 50% echogenic material). Apart from the ultrasound reference structures used in this 
protocol, the echogenicity scoring is similar to previous reports in the literature.1, 2   
      Grade 5 represents plaques that are not possible to classify on ultrasound of technical 
reasons (e.g., plaques in the far wall concealed by the echo shadow from calcified near 
wall plaques, not possible to angling of the probe to obtain representative images, plaque 
localized to high upstream to get high-quality images, etc.) 
      When a plaque is heterogeneous and consists partly of high-echogenic and partly of 
low-echogenic material, the scoring of echogenicity is based of an overall impression of 
the dominating plaque echogenicity. When more than 80% of the plaque is of a given 
echogenicity, the echogenicity is scored as if the whole plaque consisted of this 
echogenicity although the rest of the plaque echogenicity was differing 2 or 3 grades from 
the dominating class of echogenicity. If the percentage is below 80%, interpolating is 
performed by judgement.  
 
 
     Thus, plaque echogenicity is classified as follows: 
   
 Grade 1: Echolucent  (0- 20 % of plaque material is high-echogenic). 
 Grade 2: Predominant echolucent (21-50 % of plaque material is high-echogenic). 
 Grade 3: Predominant echogenic (51-79 % of plaque material is high-echogenic). 
 Grade 4: Echogenic (80-100 % of plaque material is high-echogenic). 
 Grade 5: Missing, not classifiable 
 
    In the same way, a total echogenicity status for an artery is determined if more than one 
plaque is present. The same limit of 80% is the basis of scoring of total plaque area.  







13. Do not remove the cassette from the video recorder before the end of the day, or when the   
      cassette is full. 
 
14. Check that the registration form is completed appropriately. In the ”Remarks” box,    
      coding for reasons for missing of measurable images should be done:  
   
   MB 1= missing images from BULB due to obesity. 
   MB 2= missing images from BULB due to a steep angle between CCA and BULB. 
   MB 3= missing images from BULB due to technically difficult examinations. 
   MB 4= missing images from BULB due to previous surgery or radiation. 
   MB 5= other reasons 
   In the same way, missing coding for CCA and ICA is performed: MC 1, MC 2, etc.  
 
A referral form to Department of Neurology, University Hospital, Tromsø is completed when 
a suspected carotid stenosis or occlusion are found. Two criteria for defining a stenosis are 
used. Either a velocity increase across an atherosclerotic plaque in BULB of 0.1 m/sec. or 
more or 0.2 m/sec. in ICA, compared to the reference velocity distally in ICA; or a plaque 
thickness that constitutes 35% or more of the lumen diameter at the plaque site. The 
velocities should be manually angle-corrected for the angle at which Doppler-beams are 
emitted into the vessel. Occlusion is suspected when the open lumen of the artery is not 
visible on B-mode or if there is a visible occluding plaque in the artery, and there is no 
detectable flow in the artery by pulsed Doppler or by colour-Doppler. The referral threshold 
should be low to avoid false negative stenosis cases. The person, who is referred, should be 
given a written and verbal information of the finding and clinical implications before living 
the room.       
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(Digitizing plaque images from SVHS-cassette) 
 
• PC + monitor, and Panasonic 7560 video recorder + monitor are switched on. The 
video screen is preset to PAL. 
 
• The videocassette is inserted in the video recorder. Wind on to the plaque image of 
interest. Check continuously the plaque registration form (Excel-sheet) to ensure that 
no plaque images are missed. The frame on the video screen should be smoothly 
adjusted until it is stationary, without any “snow”.  
 
• Start Matrox Intellicam on the PC desktop. 
 
• If this is the first ‘grab’ from the videocassette, the GSM-value for the background 
colour of the recorded image should be calibrated according to the following 
procedure (1-5). If not, proceed to the next step. 
 
1. Grab an image (see the procedure for GRAB!). 
2. Save the image in the catalogue C:\My documents\Plaque\Test as test.tif. 
3. Export the image to Adobe Photoshop 3.0. 
4. Press the Image mode – Greyscale, and then ’OK’ on the mini-menu 
’Discard colour information?’ 
5. Delimit a ’black’ area outside the B-mode picture on the screen with the 
squared tool function, and press Image – Histogram. The mean value 
should be between 1-3. If it is <1 or  >3, the ’BLACK LEVEL’-button on 
the Panasonic 7650’s ’TBC CONTROL’ is turned a little 
clockwise/counter-clockwise respectively, and the procedure is repeated 
until the mean value is between 1-3 (but not 0, then the ’BLACK LEVEL’ 
is too low!). This procedure should be repeated at every start-up, and each 
time a new videocassette is inserted, to ensure that background-black really 
is black.  
 
GRAB! 
• Press Ctrl + M, or press the camera-icon in the menu (nr 6 from left) to grab the 
image. Repeat until you have an optimal image. Every time Matrox Intellicam is 
started, the ‘Digitizer Configuration Format’ menu will appear on the screen – Choose 
’PAL’ in the box and press ‘OK’.  
 
• Save the image by pressing Alt+F – A, or File – Save As, (but not Ctrl+S, or Alt+F 
– S, then the previous image will be erased!) and use the file name from the plaque 
registration form. PS – check for writing error. The file is saved in the catalogue 
corresponding to the tape number (Tape 01 etc…) under Tr4 or Tr5 respectively. (To 
simplify the file name routine, the file can be copied from Excel, and pasted in the file 
name column in Intellicam, and thereafter press <Enter> to save…but still check for 
writing error!!). Fill in ’grab’ – date (format: ddmmyy, f. ex 011102, 150103) on the 
Excel sheet as a ‘receipt’. 
 
• Wind on to the next plaque recording, adjust smoothly and repeat the 
procedure…11000 times!  
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